These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 20510193)

  • 1. Early graphical appearance of radiation pneumonitis correlates with the severity of radiation pneumonitis after stereotactic body radiotherapy (SBRT) in patients with lung tumors.
    Takeda A; Ohashi T; Kunieda E; Enomoto T; Sanuki N; Takeda T; Shigematsu N
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):685-90. PubMed ID: 20510193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT).
    Wang S; Liao Z; Wei X; Liu HH; Tucker SL; Hu CS; Mohan R; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1399-407. PubMed ID: 16997503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis.
    Yamaguchi S; Ohguri T; Ide S; Aoki T; Imada H; Yahara K; Narisada H; Korogi Y
    Lung Cancer; 2013 Nov; 82(2):260-5. PubMed ID: 24054547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation pneumonitis in patients treated for malignant pulmonary lesions with hypofractionated radiation therapy.
    Borst GR; Ishikawa M; Nijkamp J; Hauptmann M; Shirato H; Onimaru R; van den Heuvel MM; Belderbos J; Lebesque JV; Sonke JJ
    Radiother Oncol; 2009 Jun; 91(3):307-13. PubMed ID: 19321217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis.
    Claude L; Pérol D; Ginestet C; Falchero L; Arpin D; Vincent M; Martel I; Hominal S; Cordier JF; Carrie C
    Radiother Oncol; 2004 May; 71(2):175-81. PubMed ID: 15110451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study.
    Feddock J; Arnold SM; Shelton BJ; Sinha P; Conrad G; Chen L; Rinehart J; McGarry RC
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1325-31. PubMed ID: 23265574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosimetric predictors of radiation-induced lung injury in stereotactic body radiation therapy.
    Ricardi U; Filippi AR; Guarneri A; Giglioli FR; Mantovani C; Fiandra C; Anglesio S; Ragona R
    Acta Oncol; 2009; 48(4):571-7. PubMed ID: 19031164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy.
    Takeda A; Kunieda E; Ohashi T; Aoki Y; Oku Y; Enomoto T; Nomura K; Sugiura M
    Chest; 2012 Apr; 141(4):858-866. PubMed ID: 21885726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer.
    De Jaeger K; Seppenwoolde Y; Kampinga HH; Boersma LJ; Belderbos JS; Lebesque JV
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1378-87. PubMed ID: 15050313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-response relationship for radiation-induced pneumonitis after pulmonary stereotactic body radiotherapy.
    Guckenberger M; Baier K; Polat B; Richter A; Krieger T; Wilbert J; Mueller G; Flentje M
    Radiother Oncol; 2010 Oct; 97(1):65-70. PubMed ID: 20605245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renin-Angiotensin System Inhibitors Might Help to Reduce the Development of Symptomatic Radiation Pneumonitis After Stereotactic Body Radiotherapy for Lung Cancer.
    Bracci S; Valeriani M; Agolli L; De Sanctis V; Maurizi Enrici R; Osti MF
    Clin Lung Cancer; 2016 May; 17(3):189-97. PubMed ID: 26427647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin-converting enzyme inhibitors decrease the risk of radiation pneumonitis after stereotactic body radiation therapy.
    Harder EM; Park HS; Nath SK; Mancini BR; Decker RH
    Pract Radiat Oncol; 2015; 5(6):e643-9. PubMed ID: 26412341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of Radiation Pneumonitis After Stereotactic Body Radiotherapy: Effect of Pulmonary Emphysema Quantitated Using CT Images.
    Yamamoto T; Kadoya N; Sato Y; Matsushita H; Umezawa R; Kubozono M; Ishikawa Y; Kozumi M; Takahashi N; Morishita Y; Katagiri Y; Sato K; Ito K; Takeda K; Jingu K
    Clin Lung Cancer; 2018 Jan; 19(1):e85-e90. PubMed ID: 28655592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
    Yom SS; Liao Z; Liu HH; Tucker SL; Hu CS; Wei X; Wang X; Wang S; Mohan R; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2007 May; 68(1):94-102. PubMed ID: 17321067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of clinical, tumour-related and dosimetric factors in grade 0-1, grade 2 and grade 3 radiation pneumonitis after stereotactic body radiotherapy for lung tumours.
    Takeda A; Ohashi T; Kunieda E; Sanuki N; Enomoto T; Takeda T; Oku Y; Shigematsu N
    Br J Radiol; 2012 May; 85(1013):636-42. PubMed ID: 22253343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation pneumonitis following concurrent accelerated hyperfractionated radiotherapy and chemotherapy for limited-stage small-cell lung cancer: Dose-volume histogram analysis and comparison with conventional chemoradiation.
    Tsujino K; Hirota S; Kotani Y; Kado T; Yoden E; Fujii O; Soejima T; Adachi S; Takada Y
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1100-5. PubMed ID: 16373082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of large stage I-II lung tumors using stereotactic body radiotherapy (SBRT): planning considerations and early toxicity.
    Ong CL; Palma D; Verbakel WF; Slotman BJ; Senan S
    Radiother Oncol; 2010 Dec; 97(3):431-6. PubMed ID: 20971523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of toxicity grade and scoring system on the relationship between mean lung dose and risk of radiation pneumonitis in a large cohort of patients with non-small cell lung cancer.
    Tucker SL; Jin H; Wei X; Wang S; Martel MK; Komaki R; Liu HH; Mohan R; Chen Y; Cox JD; Liao Z
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):691-8. PubMed ID: 19836159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The risk and predictors for severe radiation pneumonitis in lung cancer patients treated with thoracic reirradiation.
    Ren C; Ji T; Liu T; Dang J; Li G
    Radiat Oncol; 2018 Apr; 13(1):69. PubMed ID: 29661254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer.
    Ueki N; Matsuo Y; Togashi Y; Kubo T; Shibuya K; Iizuka Y; Mizowaki T; Togashi K; Mishima M; Hiraoka M
    J Thorac Oncol; 2015 Jan; 10(1):116-25. PubMed ID: 25376512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.